NCT04721821View on ClinicalTrials.gov

Comparative Effectiveness Of Tumor Necrosis Factor Inhibitors And Tofacitinib Use In Earlier Lines Of Therapy And Use As Monotherapy.

CompletedOBSERVATIONAL
Enrollment

7,807

Participants

Timeline

Start Date

January 22, 2021

Primary Completion Date

November 29, 2021

Study Completion Date

November 29, 2021

Conditions
Arthritis Rheumatoid
Interventions
DRUG

Tofacitinib

Patients who received Tofacitinib for RA

Trial Locations (1)

10017

Pfizer, New York

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT04721821 - Comparative Effectiveness Of Tumor Necrosis Factor Inhibitors And Tofacitinib Use In Earlier Lines Of Therapy And Use As Monotherapy. | Biotech Hunter | Biotech Hunter